N¹-benzyloxymethyluracil | 80140-15-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N¹-benzyloxymethyluracil
• 英文别名: 1-benzyloxymethylpyrimidine-2,4-dione；1-((benzyloxy)methyl)pyrimidine-2,4(1H,3H)-dione；1-(phenylmethoxymethyl)pyrimidine-2,4-dione
• CAS: 80140-15-4
• 化学式: C₁₂H₁₂N₂O₃
• 分子量: 232.239
• InChiKey: RYKNLEOFKVJZJM-UHFFFAOYSA-N

物化性质

• 熔点：
  135-136 °C
• 密度：
  1.258±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  N¹-benzyloxymethyluracil 在 碘代三甲硅烷 、 水 作用下， 生成 尿嘧啶
  参考文献：
  名称：

  Kundu, Nitya G., Synthetic Communications, 1981, vol. 11, # 10, p. 787 - 794

  摘要：

  DOI：
• 作为产物：
  描述：

  苄基缩水甘油醚 在 盐酸 、 lithium aluminium tetrahydride 、 zinc(II) iodide 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 反应 12.0h， 生成 N¹-benzyloxymethyluracil
  参考文献：
  名称：

  Acyclic Nucleosides: Synthesis of 1-[(1-Hydroxy-2-Propoxy) Methyl]Thymine, 6-Azathymine, URACIL, AND 6-Azauracil as Potential Antiviral Agents

  摘要：

  A series of acyclic nucleosides have been synthesized. Thymine, 6-azathymine, uracil, and 6-azauracil were silylated with hexamethyldisilazane in the presence of ammonium sulfate and then coupled with 1-benzyloxy-2-chloromethoxypropane to give the corresponding 1-(1-benzyloxy-2-propoxy)methyl derivatives. A minor quantity of benzyloxymethylated product was also obtained in each case. Hydrogenolysis of the protected acyclic nucleosides with palladium(II) hydroxide afforded the title compounds. None of the compounds exhibited significant antiviral activity against human immunodeficiency virus (HIV).

  DOI：

  10.1080/15257779408011890

文献信息

• [EN] OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS<br/>[FR] OLIGONUCLÉOTIDES CONTENANT DES ANALOGUES NUCLÉOTIDIQUES
  申请人：SANOFI SA

  公开号：WO2021044004A1

  公开（公告）日：2021-03-11

  The present disclosure relates to double-stranded oligonucleotides, including double-stranded oligonucleotides such as siRNAs, comprising a sense strand oligonucleotide and an antisense strand oligonucleotide, and wherein the antisense strand oligonucleotide comprises one or more nucleotide analogs of formula (I-A) which are neither the 5'-overhang nucleotide nor the 3'-overhang nucleotide of the said antisense strand oligonucleotide, and wherein a nucleotide analog of formula (I-A) is as described in the disclosure. Oligonucleotides containing these analogs have superior biological activity, for example, increased in vitro stability and improved in vivo potency especially improved off-target profiles. The improved oligonucleotides are useful for silencing (e.g., reducing or eradicating) the expression of a target gene.

  本公开涉及双链寡核苷酸，包括双链寡核苷酸，例如siRNA，包括一个sense链寡核苷酸和一个antisense链寡核苷酸，其中antisense链寡核苷酸包括一个或多个公式(I-A)的核苷酸类似物，这些类似物既不是所述antisense链寡核苷酸的5'-突出核苷酸也不是3'-突出核苷酸，并且公式(I-A)的核苷酸类似物如所述。含有这些类似物的寡核苷酸具有优越的生物活性，例如增加的体外稳定性和改善的体内效力，特别是改善的非靶向作用谱。改进的寡核苷酸对于沉默（例如减少或根除）靶基因的表达是有用的。
• Synthesis and anti-hiv-1 activities of 6-arylthio and 6-arylselenoacyclonucleosides
  作者：Bai-Chuan Pan、Zhi-Hao Chen、Giovanna Piras、Ginger E. Dutschman、Elizabeth C. Rowe、Yung-Chi Cheng、Shih-Hsi Chu

  DOI：10.1002/jhet.5570310130

  日期：1994.1

  6-Arylthio and 6-arylselenoacyclonucleosides was synthesized and tested for the ability to inhibit replication of HIV-1. Lithiation of acyclonucleosides with LDA followed by reaction with the electrophiles phenyl disulfide, diphenyl diselenide, 2,2′-dipyrdyl disulfide or 2,2′-dipyridyl diselenide afforded 6-(arylthio or arylseleno)acyclonucleosides 5a-c, 6, 7, 9, 15a-c, 17a-c. Compounds 19a-c and 20a-c

  合成6-芳硫基和6-芳基硒基环杂核苷，并测试其抑制HIV-1复制的能力。将无环核苷酸与LDA锂化，然后与亲电试剂苯基二硫化物，二苯基二硒化物，2,2'-二吡啶基二硫化物或2,2'-二吡啶基二硒化物反应，得到6-（芳硫基或芳基硒代）无环核苷5a-c， 6、7、9 ，15a-c，17a-c。化合物19a-c和20a-c通过相应的TBDMS衍生物的脱保护得到。在反应期间也形成了脱水产物16a和18a-c。5-乙基-6-（α-吡啶硫基或α-吡啶硒基）双取代的无环尿嘧啶6和7与AZT，DDC，DDI或D4T相比，MT-2和CEM-IW细胞系对HIV-1的活性更高。CEM-IW细胞中针对HIV-1的EC 50为6，在纳摩尔范围内，治疗指数为1100。
• [EN] 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV<br/>[FR] NUCLÉOSIDES MÉTHYLE OU ALCYNYLE SUBSTITUÉS EN POSITION 3 POUR LE TRAITEMENT DU VIRUS DE L'HÉPATITE C
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2015161137A1

  公开（公告）日：2015-10-22

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.

  本文提供了用于治疗黄病毒科感染的化合物、组合物和方法，包括HCV感染。在某些实施例中，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合使用。在某些实施例中，所述化合物是Formula I的3'-取代甲基或炔基核苷衍生物：(I)；或其药学上可接受的盐、溶剂化合物、立体异构体形式、互变异构体形式或多形形式，其中Base、PD、RA、RB1、RB2、RC和Z如本文所定义。
• Sulfonamide derivatives
  申请人：Sankyo Company, Limited

  公开号：US06673804B1

  公开（公告）日：2004-01-06

  A compound of the formula (I) or a pharmacologically acceptable salt, ester or other derivative thereof: R1 is H or NHOH. R2 is H, optionally substituted alkyl, cycloalkyl or a group —AR6. A is an alkylene which may be optionally interrupted by O, —S(O)m— or —N(R9). R6 is a group (II), (III), (IV) X is O, S, —N(R10)—, —C(R11)(R12)—. Y is O, CO, —S(O)n—, —N(R10)—, —C(R11)(R12)—. Each of R7 and R8 is H, alkyl, COOH, optionally substituted alkyl, etc. Each of R9, R10, R11, and R12 is H, alkyl, etc. Each of m and n is 0 to 2. R3 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl. R4 is optionally substituted (hetero)arylene. R5 is optionally substituted alkyl, optionally substituted (hetero)aryl. These compounds have matrixmetalloproteinase—13 inhibitory activity and aglycanase inhibitory activity.

  化合物的公式（I）或其药理学上可接受的盐，酯或其他衍生物：其中，R1为H或NHOH，R2为H，可选择性地取代的烷基，环烷基或群体-AR6，A为可选择性地由O，-S（O）m-或-N（R9）中断的烷基，R6为群体（II），（III），（IV），X为O，S，-N（R10）-，-C（R11）（R12）-，Y为O，CO，-S（O）n-，-N（R10）-，-C（R11）（R12）-，R7和R8中的每一个为H，烷基，COOH，可选择性取代的烷基等，R9，R10，R11和R12中的每一个为H，烷基等，m和n中的每一个为0到2，R3为H，可选择性取代的烷基，可选择性取代的环烷基，可选择性取代的烯基，可选择性取代的炔基，R4为可选择性取代的（杂）芳基，R5为可选择性取代的烷基，可选择性取代的（杂）芳基。这些化合物具有基质金属蛋白酶-13抑制活性和去糖基酶抑制活性。
• SULFONAMIDE DERIVATIVES
  申请人：Sankyo Company Limited

  公开号：EP1069110A1

  公开（公告）日：2001-01-17

  [Object] The object is to provide a compound having matrixmetalloproteinase-13 inhibitory activity and aglycanase inhibitory activity. [Solution] A compound of the following formula (I) or a pharmacologically acceptable salt, ester or other derivative thereof: R1: H, NHOH; R2: H, optionally substituted alkyl, cycloalkyl, a group -AR6 [A: an alkylene which may be optionally interrupted by O, -S(O)m- or -N(R9); R6: a group (II), (III), (IV) X: O, S, -N(R10)-, -C(R11)(R12)-; Y: O, CO, -S(O)n-, -N(R10)-, -C(R11)(R12)-; R7, R8: H, alkyl, COOH, optionally subsituted alkyl, etc.; R9, R10, R11, R12: H, alkyl, etc.; m, n: 0 to 2] R3: H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl; R4: optionally substituted (hetero)arylene; R5: optionally substituted alkyl, optionally substituted (hetero)aryl}.

  目的 目的是提供一种具有基质金属蛋白酶-13 抑制活性和琼脂糖酶抑制活性的化合物。 [解决方案］ 下式(I)的化合物或其药理学上可接受的盐、酯或其他衍生物： R1: H, NHOH; R2：H、任选取代的烷基、环烷基、基团 -AR6 [A：可任选被 O、-S(O)m- 或 -N(R9)打断的亚烷基；R6：基团 (II)、(III)、(IV) X：O、S、-N(R10)-、-C(R11)(R12)-； Y：O、CO、-S(O)n-、-N(R10)-、-C(R11)(R12)-； R7、R8：H、烷基、COOH、任选亚烷基等； R9、R10、R11、 R9、R10、R11、R12：H、烷基等； m、n：0 至 2］ R3：H、任选取代的烷基、任选取代的环烷基、任选取代的烯基、任选取代的炔基；R4：任选取代的（杂）芳基；R5：任选取代的烷基、任选取代的（杂）芳基}。